当前位置: X-MOL 学术Int. Arch. Allergy Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Charcot-Leyden Crystal Protein in Nasal Secretions of Patients with Nonallergic Rhinitis with Eosinophilia Syndrome.
International Archives of Allergy and Immunology ( IF 2.5 ) Pub Date : 2020-07-21 , DOI: 10.1159/000509252
Min Zhang 1, 2 , Bing Yan 1, 2 , Yang Wang 1, 2 , Chengshuo Wang 1 , Luo Zhang 3, 4, 5
Affiliation  

Introduction: Charcot-Leyden crystal (CLC) protein has been regarded as a hallmark of eosinophilic inflammation. Objective: The purpose of this study was to investigate the role and levels of CLC protein in patients with nonallergic rhinitis with eosinophilia syndrome (NARES). Methods: Overall, 39 NARES patients and 19 controls were recruited. The severity of nasal symptoms was measured by visual analogue scale and serum and local specific immunoglobulin E were determined in all patients. Nasal eosinophilia was assessed by semiquantitative analysis of eosinophils in nasal scrapings. Nasal secretion CLC protein concentrations were evaluated by ELISA. Results: CLC protein concentrations were significantly higher in NARES patients than in controls (p #x3c; 0.0001). Nasal secretion CLC protein levels were significantly correlated with the degree of eosinophilia in nasal scrapings (rs = 0.331; p = 0.04) in NARES patients. Patients with high CLC protein concentrations displayed more severe nasal symptoms than patients with low CLC protein concentrations (p = 0.0080), particularly, nasal itching (p = 0.0029). Pilot study in 8 NARES patients demonstrated that treatment for 1 month with intranasal fluticasone propionate significantly decreased the nasal secretion CLC protein concentrations from baseline levels (p = 0.0335) and markedly attenuated the degree of swelling of inferior turbinate. Conclusions: CLC protein levels are significantly higher in nasal secretions of NARES patients and associated with the degree of nasal eosinophilia and the severity of nasal symptoms. Significantly, nasal secretion CLC protein levels obviously decreased after treatment with intranasal corticosteroids, suggesting its possible role in evaluating the medical treatment.
Int Arch Allergy Immunol


中文翻译:

非过敏性鼻炎伴嗜酸性粒细胞增多症患者鼻分泌物中的夏科特莱登晶体蛋白。

简介: Charcot-Leyden晶体(CLC)蛋白被认为是嗜酸性炎症的标志。目的:本研究旨在探讨CLC蛋白在非过敏性鼻炎伴嗜酸性粒细胞增多症(NARES)患者中的作用和水平。方法:总共招募了39名NARES患者和19名对照。通过视觉模拟量表测量鼻部症状的严重程度,并测定所有患者的血清和局部特异性免疫球蛋白E。通过鼻刮片中嗜酸性粒细胞的半定量分析来评估鼻嗜酸性粒细胞增多。通过ELISA评估鼻分泌CLC蛋白浓度。结果: NARES患者的CLC蛋白浓度显着高于对照组(p#x3c; 0.0001)。在NARES患者中,鼻分泌物的鼻分泌CLC蛋白水平与嗜酸性粒细胞的程度显着相关(r s = 0.331;p = 0.04)。高CLC蛋白浓度的患者比低CLC蛋白浓度的患者表现出更严重的鼻部症状(p = 0.0080),特别是鼻痒(p = 0.0029)。在8例NARES患者中进行的初步研究表明,鼻内丙酸氟替卡松治疗1个月可显着降低鼻分泌CLC蛋白浓度(相对于基线水平)(p = 0.0335),并显着降低下鼻甲的肿胀程度。结论:NARES患者的鼻分泌物中CLC蛋白水平显着较高,并且与鼻嗜酸性粒细胞增多的程度和鼻症状的严重程度有关。鼻内激素治疗后,鼻分泌CLC蛋白水平明显降低,提示其在药物治疗中的作用。
Int Arch过敏免疫
更新日期:2020-07-21
down
wechat
bug